These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1820107)

  • 1. Fluanxol Depot in the schizophrenia maintenance treatment.
    Ciurezu T; Niţurad A; Sârbulescu A
    Rom J Neurol Psychiatry; 1991; 29(3-4):221-3. PubMed ID: 1820107
    [No Abstract]   [Full Text] [Related]  

  • 2. [Experience with depot neuroleptics].
    Arató M; Erdós A
    Orv Hetil; 1979 Apr; 120(17):1015-21. PubMed ID: 372888
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dose and serum drug level and its clinical effects during the long-term treatment of chronic schizophrenia with flupenthixol depot].
    Lipska B; Szukalski B; Nurowska K; Welbel L
    Psychiatr Pol; 1986; 20(1):1-7. PubMed ID: 3725983
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical treatment of chronic psychoses with flupenthixol-decanoate (Fluanxol-Depot)].
    Gross H; Kaltenbäck E
    Wien Klin Wochenschr; 1972 Feb; 84(5):80-4. PubMed ID: 5015880
    [No Abstract]   [Full Text] [Related]  

  • 5. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
    Gutwinski S; Müller P; Koller M
    Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flupenthixol decanoate (fluanxol depot) in the treatment of chronic schizophrenic patients.
    Haider I
    J Pak Med Assoc; 1985 Sep; 35(9):286-9. PubMed ID: 3934417
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical experiences with depot neuroleptics].
    Peterová E; Baudis P; Dvoráková M; Vencovský E
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():173-6. PubMed ID: 829618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. II. Factor analysis of the CPRS sub-scale for schizophrenia.
    Dencker SJ; Frankenberg K; Hansen V; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():29-40. PubMed ID: 6931471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experiences with Fluanxol-depot ampules in the treatment of patients with chronic psychoses].
    Schwalbe W
    Z Allgemeinmed; 1971 Dec; 47(36):1919-22. PubMed ID: 5142254
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experiences with depot form flupenthixol].
    Bruck J; Guss H
    Wien Med Wochenschr; 1971 Feb; 121(7):110-2. PubMed ID: 5545657
    [No Abstract]   [Full Text] [Related]  

  • 11. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment.
    Martyns-Yellowe IS
    West Afr J Med; 1994; 13(4):200-3. PubMed ID: 7756183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment].
    Kühn KU; Quednow BB; Landen H; Riedel M; Thiel M
    Fortschr Neurol Psychiatr; 2004 Jul; 72(7):397-403. PubMed ID: 15252753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies on flupenthixol decanoate, a depot neuroleptic of the thioxanthene group.
    Jørgensen A
    Drug Metab Rev; 1978; 8(2):235-49. PubMed ID: 720214
    [No Abstract]   [Full Text] [Related]  

  • 14. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
    [No Abstract]   [Full Text] [Related]  

  • 15. Continuation ECT in treatment-resistant schizophrenia: a controlled study.
    Chanpattana W; Chakrabhand ML; Sackeim HA; Kitaroonchai W; Kongsakon R; Techakasem P; Buppanharun W; Tuntirungsee Y; Kirdcharoen N
    J ECT; 1999 Sep; 15(3):178-92. PubMed ID: 10492856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effects of thioridazine, flupenthixol and haloperidol on serum catalase activity in schizophrenia].
    Zapletálek M
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1977; 20(2-3):197-204. PubMed ID: 305641
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of schizophrenia with trifluoperazine].
    Wojdyslawska I
    Psychiatr Pol; 1976; 10(6):703-4. PubMed ID: 1013252
    [No Abstract]   [Full Text] [Related]  

  • 18. [Overcoming resistance to therapy in schizophrenia].
    Poliachenko AB; Mogilianskaia FN
    Vrach Delo; 1985 Aug; (8):110-1. PubMed ID: 2866630
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experiences with the depot-neuroleptic agent Dapotum D].
    Teutsch H; Boissi KW
    Med Welt; 1974 Nov; 25(48):2027-32. PubMed ID: 4459664
    [No Abstract]   [Full Text] [Related]  

  • 20. Radioreceptor assay in checking serum concentration in long-term treatment with cis(z)-flupenthixol decanoate.
    Lipska B; Welbel L; Nurowska K; Szukalski B
    Act Nerv Super (Praha); 1987 Dec; 29(4):270-3. PubMed ID: 3439426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.